Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH

Watchlist Manager
Reviva Pharmaceuticals Holdings, Inc. Logo
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Watchlist
Price: 1.78 USD 8.54%
Market Cap: 59.5m USD
Have any thoughts about
Reviva Pharmaceuticals Holdings, Inc.?
Write Note

Reviva Pharmaceuticals Holdings, Inc.
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Reviva Pharmaceuticals Holdings, Inc.
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
Cash Interest Paid
$24k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Cash Interest Paid
$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Cash Interest Paid
$2.9B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
7%
Merck & Co Inc
NYSE:MRK
Cash Interest Paid
$1.2B
CAGR 3-Years
16%
CAGR 5-Years
7%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Reviva Pharmaceuticals Holdings, Inc.
Glance View

Market Cap
59.5m USD
Industry
Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.

RVPH Intrinsic Value
2.42 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Reviva Pharmaceuticals Holdings, Inc.'s Cash Interest Paid?
Cash Interest Paid
24k USD

Based on the financial report for Sep 30, 2024, Reviva Pharmaceuticals Holdings, Inc.'s Cash Interest Paid amounts to 24k USD.

What is Reviva Pharmaceuticals Holdings, Inc.'s Cash Interest Paid growth rate?
Cash Interest Paid CAGR 1Y
18%

Over the last year, the Cash Interest Paid growth was 18%.

Back to Top